Kronik hepatit C'li hastalarda direkt etkili antivirallerin etkinliğinin retrospektif olarak değerlendirilmesi
Yükleniyor...
Tarih
2024
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Necmettin Erbakan Üniversitesi, Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
AMAÇ
Bu çalışmada HCV RNA pozitifliği olan hastalara başlanan direkt etkili antiviral ilaçların tedavi etkinliğinin değerlendirilmesi amaçlanmıştır.
YÖNTEM
Bu retrospektif çalışmada 01 Ocak 2015 - 01 Mart 2023 tarihleri arasında Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi Hastanesi’nde HCV RNA pozitif direkt etkili antiviral başlanan hastalar dahil edilmiştir
BULGULAR
Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi Hastanesi Gastroenteroloji Anabilim Dalı’nda yapılan bu çalışmaya 2015-2023 tarihleri arasında başvuran ve Hepatit C Virüsü (HCV) pozitif olan 146 hasta dahil edildi. Hastaların %56,8’i (n=83) erkek, yaş ortalaması 53,75±19,97 yıl idi. HCV genotiplemesine göre 83 (%56,8) hastanın tip1b, 34 (%23,3) hastanın tip3 olduğu kaydedildi. HCV pozitif olan hastaların %21,9’unda (n=32) iv madde kullanımı, %22,6’sında (n=33) siroz, %4,8’inde (n=7) hepatoselüler karsinom (HCC) mevcuttu. Hastalarda kullanılan tedavi grupları (Glecaprevir + Pibrentasvir), (Ombitasvir + Paritaprevir + Ritonavir + Dasabuvir), (Ledipasvir + Sofosbuvir + Ribavirin), (Ledipasvir + Sofosbuvir), (Ombitasvir +Paritaprevir + Ritonavir + Dasabuvir + Ribavirin) olarak belirlendi. İlaç grupları arasında SVR yanıtı açısından bir fark saptanmadı. Hastaların zamanla HCV RNA değişiminde istatistiksel olarak anlamlı düzeyde azalma tespit edilmiştir (p<0,001). Başlangıca göre tedavinin 4. haftası, 12. haftası ve 12. ayında HCV RNA düzeyinin anlamlı düzeyde düştüğü tespit edildi (p<0,001).
SONUÇ
Kronik hepatit C’li hastalarda direkt etkili antivirallerin hastalığın tedavisinde etkinliği çok yüksek olduğu vurgulanmaktadır. Kronik hepatit C tedavisinde direkt etkili antivirallerin kullanımının yaygınlaştırılması ve direkt etkili antiviral ajanlara ulaşımın kolaylaştırılması gerekmektedir.
PURPOSE This study aimed to evaluate the treatment effectiveness of direct-acting antiviral drugs administered to patients with HCV RNA positivity. METHOD In this retrospective study, patients who started direct-acting antiviral treatment for HCV RNA positivity between January 1, 2015, and March 1, 2023, at Necmettin Erbakan University Meram Faculty of Medicine Hospital were included. RESULTS A study conducted at the Department of Gastroenterology, Necmettin Erbakan University Meram Medical Faculty Hospital, included 146 patients who tested positive for Hepatitis C Virus (HCV) between 2015 and 2023. Of these patients, 56.8% (n=83) were male, with a mean age of 53.75 ± 19.97 years. According to HCV genotyping, it was recorded that 56.8% (83 patients) had genotype 1b, while 23.3% (34 patients) had genotype 3. Among HCV-positive patients, 21.9% (n=32) reported intravenous drug use, 22.6% (n=33) had cirrhosis, and 4.8% (n=7) had hepatocellular carcinoma (HCC). The treatment groups administered to the patients were defined as follows: Glecaprevir + Pibrentasvir, Ombitasvir + Paritaprevir + Ritonavir + Dasabuvir, Ledipasvir + Sofosbuvir + Ribavirin, Ledipasvir + Sofosbuvir, Ombitasvir + Paritaprevir + Ritonavir + Dasabuvir + Ribavirin. No significant difference in sustained virologic response (SVR) was observed between the drug groups. Statistically significant decreases in HCV RNA levels over time were found among the patients (p<0.001). Significant reductions in HCV RNA levels were noted at the 4th week, 12th week, and 12th month of treatment compared to baseline (p<0.001). CONCLUSION Direct-acting antivirals demonstrate high effectiveness in the treatment of chronic hepatitis C patients. It is emphasized that the use of direct-acting antivirals in the treatment of chronic hepatitis C should be expanded, and access to direct-acting antiviral agents should be facilitated
PURPOSE This study aimed to evaluate the treatment effectiveness of direct-acting antiviral drugs administered to patients with HCV RNA positivity. METHOD In this retrospective study, patients who started direct-acting antiviral treatment for HCV RNA positivity between January 1, 2015, and March 1, 2023, at Necmettin Erbakan University Meram Faculty of Medicine Hospital were included. RESULTS A study conducted at the Department of Gastroenterology, Necmettin Erbakan University Meram Medical Faculty Hospital, included 146 patients who tested positive for Hepatitis C Virus (HCV) between 2015 and 2023. Of these patients, 56.8% (n=83) were male, with a mean age of 53.75 ± 19.97 years. According to HCV genotyping, it was recorded that 56.8% (83 patients) had genotype 1b, while 23.3% (34 patients) had genotype 3. Among HCV-positive patients, 21.9% (n=32) reported intravenous drug use, 22.6% (n=33) had cirrhosis, and 4.8% (n=7) had hepatocellular carcinoma (HCC). The treatment groups administered to the patients were defined as follows: Glecaprevir + Pibrentasvir, Ombitasvir + Paritaprevir + Ritonavir + Dasabuvir, Ledipasvir + Sofosbuvir + Ribavirin, Ledipasvir + Sofosbuvir, Ombitasvir + Paritaprevir + Ritonavir + Dasabuvir + Ribavirin. No significant difference in sustained virologic response (SVR) was observed between the drug groups. Statistically significant decreases in HCV RNA levels over time were found among the patients (p<0.001). Significant reductions in HCV RNA levels were noted at the 4th week, 12th week, and 12th month of treatment compared to baseline (p<0.001). CONCLUSION Direct-acting antivirals demonstrate high effectiveness in the treatment of chronic hepatitis C patients. It is emphasized that the use of direct-acting antivirals in the treatment of chronic hepatitis C should be expanded, and access to direct-acting antiviral agents should be facilitated
Açıklama
Anahtar Kelimeler
Direkt etkili antiviral (DAA), Direct-acting antiviral (DAA), hepatit C virüsü, hepatitis C virus, HCV RNA, kalıcı virolojik yanıt (SVR), sustained virological response (SVR)
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Türkmenoğlu, Y. C. (2024). Kronik hepatit C'li hastalarda direkt etkili antivirallerin etkinliğinin retrospektif olarak değerlendirilmesi. (Yayınlanmamış tıpta uzmanlık tezi) Necmettin Erbakan Üniversitesi, Tıp Fakültesi Dahili Tıp Bilimleri Bölümü İç Hastalıkları Anabilim Dalı, Konya.
